Clinical applications of antineutrophil cytoplasmic antibody testing

Current Opinion in Rheumatology

Volumn 16, Issue 1, 2004, Pages 9-17

  Schmitt, Wilhelm H ^a,b   Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antineutrophil cytoplasmic antibodies; Microscopic polyangiitis; Vasculitis; Wegener granulomatosis

Indexed keywords

MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY SCREENING; ANTIBODY TITER; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; LABORATORY DIAGNOSIS; MEDICAL DECISION MAKING; MICROSCOPIC POLYANGIITIS; PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SOLID; STANDARDIZATION; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0346786220     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200401000-00004     Document Type: Review

References (59)

1. van der Woude FJ, Daha MR, van Es LA: The current status of neutrophil cytoplasmic antibodies. Clin Exp Immunol 1989, 78:143-148.
2. van der Woude FJ: Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits. Nephrol Dial Transplant 2002, 17:2081-2083.
3. Jennette JC, Falk RJ, Andrassy K, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
4. Falk RJ, Jennette JC: ANCA are pathogenic - oh yes they are! J Am Soc Nephrol 2002, 13:1977-1979.
5. Xiao H, Heeringa P, Hu P, et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963. An elegant mouse model of anti-MPO disease demonstrates that MPO ANCAs have the potential to induce crescentic glomerulonephritis and vasculitis in the absence of B and T cells.
6. Wiik A: Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford) 2002, 41:481-483. This is an excellent and comprehensive review of the methods of ANCA detection, the standardization of ANCA assays, and ANCA antigens.
7. Savige JA, Paspaliaris B, Silvestrini R, et al.: A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J Clin Pathol 1998, 51:568-575.
8. Wiik A: Neutrophil-specific autoantibodies in chronic inflammatory bowel diseases. Autoimmunol Rev 2002, 1:67-72. This review highlights important differences between neutrophil-specific autoantibodies typically found in chronic inflammatory bowel disease and ANCAs.
9. Terjung B, Herzog V, Worman HJ, et al: Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998, 28:332-340.
10. Jethwa HS, Nachman PH, Falk RJ, et al.: False-positive myeloperoxidase binding activity due to DNA/anti-DNA antibody complexes: a source for analytical error in serologic evaluation of anti-neutrophil cytoplasmic autoantibodies. Clin Exp Immunol 2000, 121:544-550.
11. Csernok E, Ahlquist D, Ullrich S, et al.: A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis. Rheumatology (Oxford) 2002, 41:1313-1317. This is an important study because it reports that most commercial direct ELISA kits for the determination of PR3 ANCA and MPO ANCA achieve a poor sensitivity for both WG and MPA.
12. Hagen EC, Andrassy K, Chernok E, et al.: The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods 1993, 159:1-16.
13. Hagen EC, Andrassy K, Csernok E, et al.: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996, 196:1-15.
14. Hagen EC, Daha MR, Hermans J, et al.: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998, 53:743-753.
15. Savige J, Gillis D, Benson E, et al.: International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999, 111:507-513.
16. Pollock W, Clarke K, Gallagher K, et al.; Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate. J Clin Pathol 2002, 55:680-683. The investigators report that IIIF patterns seen with ANCA positive sera may vary even in reference laboratories despite adherence to standardized conditions.
17. Wang G, Csernok E, de Groot K, et al.: Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA). J Immunol Methods 1997, 208:203-211.
18. Russell KA, Wiegert E, Schroeder DR, et al.: Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002, 103:196-203. The investigators evaluated different algorithms for ANCA testing under routine clinical conditions. Screening of sera by MPO-and PR3-specific direct ELISA followed by IIF for confirmation of positive findings was reported to yield the highest diagnostic accuracy for AASV and to result in significant labor savings.
19. Stone JH, Stebbing J, Uhlfelder ML, et al.: Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000, 13:424-434.
20. Westman KW, Selga D, Bygren P, et al.: Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. Kidney Int 1998, 53:1230-1236.
21. Boomsma MM, Damoiseaux JG, Stegeman CA, et al.: Image analysis: a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis. J Immunol Methods 2003, 274:27-35. The paper outlines an innovative model for automated quantification of ANCA titers using an IIF technique.
22. van der Geld YM, Oost-Kort W, Limburg PC, et al.: Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods 2000, 244:117-131.
23. van der Geld YM, Smook ML, Huitema MG, et al.: Expression of recombinant proteinase 3, the autoantigen in Wegener's granulomatosis, in insect cells. J Immunol Methods 2002, 264:195-205. The investigators expressed different forms of recombinant PR3 I insect cells, which may be used as a tool for diagnostic tests as well as for epitope mapping studies.
24. Specks U, Wiegert EM, Homburger HA: Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for antineutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 1997, 109:286-295.
25. Boomsma MM, Stegeman CA, Oost-Kort WW, et al.: Native and recombinant proteins to analyze auto-antibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis. J Immunol Methods 2001, 254:47-58.
26. Gal AA, Velasquez A: Antineutrophil cytoplasmic autoantibody in the absence of Wegener's granulomatosis or microscopic polyangiitis: implications for the surgical pathologist. Mod Pathol 2002, 15:197-204.
27. Wu YY, Hsu TC, Chen TY, et al.: Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol 2002, 128:347-352.
28. McLaren JS, Stimson RH, McRorie ER, et al.: The diagnostic value of antineutrophil cytoplasmic antibody testing in a routine clinical setting. QJM 2001, 94:615-621.
29. Flores-Suarez LF, Cabiedes J, Villa AR, et al.: Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology (Oxford) 2003, 42:223-229. This paper is important because it underscores the association of tuberculosis with both PR3 ANCA and MPO ANCA.
30. Williams MJ, Walker RJ: When is an ANCA an anchor? Intern Med J 2001, 31:308-311.
31. Watts RA, Scott DG, Lane SE: Epidemiology of Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. Cleve Clin J Med 2002, 69(suppl 2);S1184-S1186. The paper summarizes the epidemiology of AASV based on data prospectively collected over many years within a well-defined region in England.
32. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al.: No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford) 2002, 41:540-549. This carefully performed prospective study presents registry-based data on the incidences of the different vasculitides in rural versus municipal regions of southern and northern Germany.
33. Mandl LA, Solomon DH, Smith EL, et al.: Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 2002, 162:1509-1514. The authors report that compliance with ordering guidelines for ANCA testing may decrease the number of false-positive results and may have the potential to reduce total test expenditures.
34. Ruffatti A, Sinico RA, Radice A, et al.: Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol 2002, 29:918-923.
35. Khanna D, Aggarwal A, Bhakuni DS, et al.: Bactericidal/permeability- increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 2003, 30:1248-1252.
36. Vassilopoulos D, Niles JL, Villa-Forte A, et al.: Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multi-organ dysfunction. Arthritis Rheum 2003, 49:151-155. The paper underscores the importance of combining HF with antigen-specific assays to improve the diagnostic yield of ANCA testing.
37. Merkel PA: Drug-induced vasculitis. Rheum Dis Clin North Am 2001, 27:849-862.
38. van der Woude FJ, Rasmussen N, Lobatto S, et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985, 1:425-429.
39. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al.: Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989, 149:2461-2465.
40. Hoffman GS, Kerr GS, Leavitt RY, et al.: Wegener granulomatosis: an analysis of 158 patients, Ann Intern Med 1992, 116:488-498.
41. Gordon M, Luqmani RA, Adu D, et al.: Relapses in patients with a systemic vasculitis. QJM 1993, 86:779-789.
42. Nachman PH, Hogan SL, Jennette JC, et al.: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33-39.
43. Stegeman CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002, 17:2077-2080. This excellent review summarizes data on ANCA specificity and relapse rate and on ANCA titers and relapse rate.
44. Girard T, Mahr A, Noel LH, et al.: Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001, 40:147-151.
45. Slot MC, Tervaert JW, Franssen CF, et al.: Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003, 63:670-677. The authors of this important contribution identified renal relapses as the most important factor influencing long-term renal survival in patients with AASV.
46. Jayne DR, Gaskin G, Pusey CD, et al.: ANCA and predicting relapse in systemic vasculitis. QJM 1995, 88:127-133.
47. Slot MC, Boomsma MM, Kallenberg CG, et al.: A positive PR3-ANCA titer at switch to azathioprine therapy is associated with a disquieting relapse rate in ANCA-related vasculitis [abstract]. Cleve Clin J Med 2002, 69(suppl 2):S11-175. This retrospective study, which has only been published as an abstract, raises the question of whether patients with AASV in clinical remission should be switched to a remission maintenance regimen as long as the ANCA test is still positive.
48. Kyndt X, Reumaux D, Bridoux F, et al.: Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999, 106:527-533.
49. De'Oliviera J, Gaskin G, Dash A, et al.: Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995, 25:380-389.
50. Egner W, Chapel HM: Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990, 82:244-249.
51. Cohen Tervaert JW, Huitema MG, Hene RJ, et al.: Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990, 336:709-711.
52. Chan TM, Frampton G, Jayne DR, et al.: Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993, 22:387-392.
53. Kerr GS, Fleisher TA, Hallahan CW, et al.: Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. Adv Exp Med Biol 1993, 336:411-414.
54. Davenport A, Lock RJ, Wellington T: Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995, 15:201-207.
55. Boomsma MM, Stegeman CA, van der Leij MJ, et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025-2033.
56. Nowack R, Grab I, Flores-Suarez LF, et al.: ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2001, 16:1631-1637.
57. Ara J, Mirapeix E, Rodriguez R, et al.: Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999, 14:1667-1672.
58. Gisslen K, Wieslander J, Westberg G, et al.: Relationship between antineutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J Intern Med 2002, 251:129-135.
59. Han WK, Choi HK, Roth RM, et al.: Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003, 63:1079-1085.